Former Expeditors CFO Bradley S. Powell joins Trupanion board
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Trupanion appointed Bradley S. Powell to its board of directors. Powell, 65, is an independent director under Nasdaq rules and brings extensive public-company finance experience. He served as Chief Financial Officer of Expeditors International from 2008 to 2025 and previously was CFO of Eden Bioscience from 1998 to 2008, where he led its 2000 IPO.
Powell will serve until the 2026 annual meeting of stockholders. He has no arrangements related to his appointment, no family relationships with Trupanion’s leadership, and no material interests in related-party transactions. Trupanion entered into its standard indemnification agreement with him, and he will participate in the Compensation Program for Non-Employee Directors.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 5.02, 9.01
2 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
FAQ
Who did Trupanion (TRUP) appoint to its board?
Trupanion appointed Bradley S. Powell as a director.
Is Bradley S. Powell considered independent under Nasdaq rules?
Yes. He is an independent director under Nasdaq listing standards.
What is Bradley S. Powell’s prior experience?
He was CFO of Expeditors International from 2008–2025 and CFO of Eden Bioscience from 1998–2008, leading its 2000 IPO.
How long is Powell’s term on the Trupanion board?
He will serve until the 2026 annual meeting of stockholders.
Will Bradley S. Powell receive standard director protections and pay?
Yes. He signed Trupanion’s standard indemnification agreement and will join the Compensation Program for Non-Employee Directors.